Silymarin inhibits endothelial progenitor cells' senescence and protects against the antiproliferative activity of rapamycin: Preliminary study

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 6, 2010, Pages 610-618

  Parzonko, Andrzej ^a   Naruszewicz, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Endothelial progenitor cells; Rapamycin; Silymarin

Indexed keywords

BETA GALACTOSIDASE; RAPAMYCIN; SILYMARIN; TELOMERASE;

ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CELL PROTECTION; COLONY FORMATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STEM CELL;

CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; SILYMARIN; SIROLIMUS; STEM CELLS;

EID: 78751650655     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f78dc3     Document Type: Article

References (36)

1. Scott SM, Barth MG, Gaddy LR, et al. The role of circulating cells in the healing of vascular prostheses. J Vasc Surg. 1994;19:585-593.
2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science. 1997;275:964-967.
3. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634-637.
4. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005;23:97-104.
5. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation and function. Circulation. 2004;109:2058-2067.
6. Imanishi T, Hano T, Sawamura T, et al. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol. 2004;31:407-413.
7. Zhu JH, Chen JZ,Wang XX, et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol. 2006;40:648-652.
8. Kränkel N, Adams V, Linke A, et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol. 2005;25:698-703.
9. Michaud SE, Dussault S, Haddad P, et al. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis. 2006;187:423-432.
10. Imanishi T, Kobayashi K, Kuki S, et al. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis. 2006;189:288-296.
11. Butzal M, Loges S, Schweizer M, et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res. 2004;300:65-71.
12. Corchete P. Silybum marianum (L.) Gaertn: the source of silymarin. In: Ramowat KG, Merillon JM, eds. Bioactive Molecules and Medicinal Plants. Berlin/Heidelberg, Germany: Springer; 2008:123-148.
13. Sonnenbichler J, Mattersberger J, Rosen H. Stimulation of RNA synthesis in rat liver and isolated hepatocytes by silybin, an antihepatotoxic agent from Silybum marianum L. Gaertn. Hoppe Seylers Z Physiol Chem. 1976; 357:1171-1180.
14. Sonnenbichler J, Zetl I. Mechanism of action of silibinin, V: effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo. Hoppe Seylers Z Physiol Chem. 1984;365:555-566.
15. Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res. 1986;213:319-331.
16. Sonnenbichler J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines. Biochem Pharmacol. 1986;35: 538-541.
17. Láng I, Deák G, Müzes G, et al. Effect of the natural bioflavonoid antioxidant silymarin on superoxide dismutase (SOD) activity and expression in vitro. Biotechnol Ther. 1993;4:263-270.
18. Soto C, Recoba R, Barro'n H, et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol. 2003;136:205-212.
19. Saliou C, Rihn B, Cillard J, et al. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett. 1998;440:8-12.
20. Schümann J, Prockl J, Kiemer AK, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003;39:333-340.
21. Wang MJ, Lin WW, Chen HL, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci. 2002;16:2103-2112.
22. Kang JS, Jeon YJ, Kim HM, et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther. 2002;302:138-144.
23. Kang JS, Jeon YJ, Park SK, et al. Protection against lipopolysaccharideinduced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol. 2004;67:175-181.
24. El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycininduced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46:2422-2428.
25. Soto C, Mena R, Luna J, et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci. 2004;75: 2167-2180.
26. Sonnenbichler J, Scalera F, Sonnenbichler I, et al. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther. 1999;290:1375-1383.
27. Timmermans F, Plum J, Yöder MC, et al. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2009;13:87-102.
28. Papathanasopoulos A, Giannoudis PV. Biological considerations of mesenchymal stem cells and endothelial progenitor cells. Injury Int J Care Injured. 2008;39:S21-S32.
29. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92:9363-9367.
30. Steg PG, Fox KA, Eagle KA, et al. Global registry of acute coronary events (GRACE) investigators. Mortality following placement of drugeluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the global registry of acute coronary events. Eur Heart J. 2009;30:321-329.
31. Patel N, Joseph C, Corcoran GB, et al. Silymarin modulates doxorubicininduced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol Appl Pharmacol. 2010;245:143-152.
32. Xia L,Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Aktdependent mechanism. Br J Pharmacol. 2008;155:387-394.
33. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004;279:6190-6195.
34. Xie XD, Zhu JH, Wang XX, et al. Ginkgo biloba extract reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Cardiovasc Pharmacol. 2007;49:111-115.
35. Zhu JH, Wang XX, Shang YP, et al. Puerarin reduces endothelial progenitor cell senescence through augmentation of telomerase activity. Curr Vasc Pharmacol. 2008;49:106-110.
36. Feng Z, Zhang H, Levine AJ, et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A. 2007;102: 8204-8209.